Planes-Laine Gabrielle, Rochigneux Philippe, Bertucci François, Chrétien Anne-Sophie, Viens Patrice, Sabatier Renaud, Gonçalves Anthony
Department of Medical Oncology, Aix-Marseille University, Inserm U1068, CNRS UMR7258, Institute Paoli-Calmettes, 13009 Marseille, France.
CRCM-Tumor Immunology laboratory, Aix-Marseille University, Inserm U1068, CNRS UMR7258, Institute Paoli-Calmettes, 13009 Marseille, France.
Cancers (Basel). 2019 Jul 22;11(7):1033. doi: 10.3390/cancers11071033.
Recently, the development of immunotherapy through the immune checkpoint blockade led to long-lasting responses in several types of cancers that are refractory to conventional treatments, such as melanoma or non-small cell lung cancer. Immunotherapy has also demonstrated significant improvements in various other types of cancers. However, breast cancer remains one of the tumors that have not experienced the explosion of immunotherapy yet. Indeed, breast cancer was traditionally considered as being weakly immunogenic with a lower mutational load compared to other tumor types. In the last few years, anti-PD1/PD-L1 (Programmed death-ligand 1) agents have been evaluated in breast cancer, particularly in the triple negative subtype, with promising results observed when delivered as monotherapy or in combination with conventional treatments. In this review, we will report the results of the most recent studies evaluating immune checkpoint inhibitors in breast cancer. In addition, we will discuss the concomitant development of possible biomarkers, which is required for improving the selection of patients with the highest probability of benefiting from these agents.
最近，通过免疫检查点阻断进行的免疫疗法取得了进展，在几种对传统治疗难治的癌症类型中产生了持久反应，如黑色素瘤或非小细胞肺癌。免疫疗法在其他多种癌症类型中也显示出显著改善。然而，乳腺癌仍然是尚未经历免疫疗法爆发式发展的肿瘤之一。实际上，传统上乳腺癌被认为免疫原性较弱，与其他肿瘤类型相比突变负荷较低。在过去几年中，抗PD1/PD-L1（程序性死亡配体1）药物已在乳腺癌中进行评估，特别是在三阴性亚型中，单药治疗或与传统治疗联合使用时观察到了有前景的结果。在本综述中，我们将报告评估乳腺癌中免疫检查点抑制剂的最新研究结果。此外，我们将讨论可能的生物标志物的同步发展，这对于改善选择最有可能从这些药物中获益的患者是必要的。
